CD8A and neoplasm: In various solid and hematological tumors, blockade of the PD-1/PD-L1 pathway has proven to reverse this immune inhibition by restoring both antitumor function and number of tumor-infiltrating CD8+ effector T cells, resulting in reduced tumor size and increased overall survival (45–49).